Literature DB >> 27591943

Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer's disease.

Dongdong Sun1, Nuan Li1, Weiwei Zhang1, Zhiwei Zhao1, Zhipeng Mou1, Donghui Huang1, Jie Liu2, Weiyun Wang3.   

Abstract

Dysfunctional interaction of amyloid-β (Aβ) with excess metal ions is proved to be related to the etiology of Alzheimer's disease (AD). Hence, disruption of these metal-peptide interactions using nanoparticles (NPs) holds considerable promise as a therapeutic strategy to combat this incurable disease. Given that quercetin is a natural product, the biocompatibility and small size essential for permeating the blood-brain barrier make it a potential therapeutic drug candidate for treating AD. Nanocarriers formulated with the US Food and Drug Administration-approved biocompatible and biodegradable polymer PLGA are being widely explored for the controlled delivery of therapeutic drugs, proteins, peptides, oligonucleotides, and genes. With this background, the present study was undertaken to investigate the effects of PLGA-functionalized quercetin (PLGA@QT) NPs on inhibited and disassembled Aβ42 fibrils and the PLGA@QT NPs have low cytotoxicity when tested on SH-SY5Y cells in vitro. As expected, the cytotoxicity studies of the PLGA@QT NPs led to a concentration-related behaviour on the SH-SY5Y human neuroblastoma cells. And, it has demonstrated that PLGA@QT NPs can inhibit the neurotoxicity of Zn2+-Aβ42 system and enhance the viability of neuron cells. The results from behavioral tests indicate that injection of PLGA@QT NPs into APP/PS1 mice ameliorate cognition and memory impairments. Most encouragingly, the in vivo systemic toxicity of PLGA@QT NPs examined by histological analysis in major organs did not show any signs of adverse effect to mice. Thus, the prepared quercetin based nanoscale drug delivery carrier efficiently enhanced the therapeutic index and reduced the side effects. Our findings are highly encouraging, providing substantial evidence of the safety of PLGA@QT NPs for biomedical application. We expect these findings will be relevant for other NPs for treatment of AD and have broad implications in NP-based studies and applications.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid β; Nanoparticles; PLGA; Quercetin

Mesh:

Substances:

Year:  2016        PMID: 27591943     DOI: 10.1016/j.colsurfb.2016.08.052

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  25 in total

1.  The transcription factor XBP1 in memory and cognition: Implications in Alzheimer disease.

Authors:  Moustapha Cissé; Eric Duplan; Frédéric Checler
Journal:  Mol Med       Date:  2017-01-04       Impact factor: 6.354

Review 2.  Nanotechnology to improve the Alzheimer's disease therapy with natural compounds.

Authors:  Maria João Ramalho; Stephanie Andrade; Joana Angélica Loureiro; Maria do Carmo Pereira
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

Review 3.  Reactive oxygen species-responsive drug delivery systems for the treatment of neurodegenerative diseases.

Authors:  William C Ballance; Ellen C Qin; Hee Jung Chung; Martha U Gillette; Hyunjoon Kong
Journal:  Biomaterials       Date:  2019-06-21       Impact factor: 12.479

Review 4.  Emerging Novel Approaches for the Enhanced Delivery of Natural Products for the Management of Neurodegenerative Diseases.

Authors:  Akshay Bandiwadekar; Jobin Jose; Maryam Khayatkashani; Solomon Habtemariam; Hamid Reza Khayat Kashani; Seyed Mohammad Nabavi
Journal:  J Mol Neurosci       Date:  2021-10-25       Impact factor: 3.444

5.  Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro.

Authors:  Feng-Juan Gao; Sheng-Hai Zhang; Ping Xu; Bo-Qi Yang; Rong Zhang; Yun Cheng; Xu-Jiao Zhou; Wan-Jing Huang; Min Wang; Jun-Yi Chen; Xing-Huai Sun; Ji-Hong Wu
Journal:  Front Mol Neurosci       Date:  2017-09-07       Impact factor: 5.639

Review 6.  Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities.

Authors:  Muhammad Ovais; Nashmia Zia; Irshad Ahmad; Ali Talha Khalil; Abida Raza; Muhammad Ayaz; Abdul Sadiq; Farhat Ullah; Zabta Khan Shinwari
Journal:  Front Aging Neurosci       Date:  2018-10-23       Impact factor: 5.750

Review 7.  Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go.

Authors:  Pragya Prasanna; Arun Upadhyay
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-27

8.  PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice.

Authors:  Na Huang; Shuai Lu; Xiao-Ge Liu; Jie Zhu; Yu-Jiong Wang; Rui-Tian Liu
Journal:  Oncotarget       Date:  2017-09-15

9.  PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies.

Authors:  Marcelle Silva-Abreu; Ana Cristina Calpena; Pol Andrés-Benito; Ester Aso; Ignacio A Romero; David Roig-Carles; Radka Gromnicova; Marta Espina; Isidre Ferrer; María Luisa García; David Male
Journal:  Int J Nanomedicine       Date:  2018-09-20

10.  Designing Aptamer-Gold Nanoparticle-Loaded pH-Sensitive Liposomes Encapsulate Morin for Treating Cancer.

Authors:  Xiaoyuan Ding; Chenyang Yin; Weiwei Zhang; Yu Sun; Zhenzhen Zhang; Endong Yang; Dongdong Sun; Weiyun Wang
Journal:  Nanoscale Res Lett       Date:  2020-03-30       Impact factor: 4.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.